clinical recurrence (CR), defined as positive imaging during follow-up. The first site of clinical recurrence was compared among the three groups. Multivariable analysis tested the association between groups and CR RESULTS: Median follow-up was 36 months. At Kaplan-Meier analysis CR-free survival at 3-yr follow-up was 52%, 37%, and 40% in eSLND, tSLND and tSBRT group, respectively (p<0.0001). No statistically significant differences were observed between tSLND and tSBRT (p[0.6). These results were confirmed at multivariable analyses, where tSLND (HR: 1.41; p[0.014) and tSBRT (HR: 1.60; p[0.001) were significantly associated with a higher risk of CR. On the contrary, tSBRT did not confer a significantly higher risk of CR compared to tSLND (HR: 1.13; p[0.6). The site of CR was not significantly different among the three groups including pelvic nodes (38% vs 39% vs 37%), retroperitoneal nodes (19% vs 22% vs 30%), bone (27% vs 27% vs 27%), and visceral organs (10% vs 11% vs 6%) (all p>0.1). Finally, HTfree survival was not significantly different among the three groups at 3-yr follow-up (48% vs 46% vs 47%) (p[0.6) CONCLUSIONS: We report the largest series of patients comparing eSLND vs tSLND vs tSBRT. We observed a significantly higher CR-free survival in patients treated with an extended approach thus reflecting a possible significant under-estimation of imaging at relapse. Our data support the use of extended treatment for patients diagnosed with nodal recurrence
INTRODUCTION AND OBJECTIVES: Clinicians may offer abiraterone plus prednisone (ABI), enzalutamide (ENZA), or sipuleucel-T (SIP-T) to patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). The objective of this research was to indirectly compare the treatment effects between ABI, ENZA, and SIP-T using number needed to treat to benefit (NNTB). Pertreated-patient costs and cost per-responder are also calculated.
METHODS: Defined as the reciprocal of the absolute risk reduction (ARR), NNTB is the average number of patients needed to be treated to prevent death in 1 additional patient compared to control. The analysis was based on primary data from 3 randomized controlled trials (COU-AA-302, IMPACT, and PREVAIL). The 12-mo and 24-mo ARR estimates and NNTB values were derived from published KaplanMeier curves for overall survival (OS). The total drug expenditures needed to achieve these incremental OS benefits (i.e., cost per NNTB) were calculated by multiplying the cost of the brand drug (2018 Medicare Part-B or Part-D drug price), times each NNTB value, and by the drug's median duration of treatment. For SIP-T, drug costs were averaged over the 24-mo.
RESULTS: The NNTB values to prevent 1 additional mCRPC patient death at 12-mo were estimated at: SIP-T [ 12, ENZA [ 15, and ABI [ 100 (Table 1) . At 24-mo, the NNTB values were estimated at: SIP-T [ 10, ENZA [ 12, and ABI [ 16. Median treatment costs for each drug: SIP-T [ $130, 258, ENZA [ $194, 343, and ABI [ $151, 438. Total drug costs to obtain an additional patient alive at 12-mo was $1,563,099 for SIP-T; $2,107,332 for ENZA; and $13,168,560 for ABI. At 24-mo, drug costs for these NNTB outcomes ranged from $651,291 for SIP-T, $2,332,114 for ENZA, and $2,423,015 for ABI. SIP-T had $0 (zero) incremental costs in year-2 of treatment.
CONCLUSIONS: This NNTB analysis shows that the clinical benefit of OS in mCRPC patients treated with SIP-T compares favorably to ENZA and ABI over time. The estimated total drug cost to achieve an additional patient OS benefit is lower for SIP-T and declines over time compared to either ENZA or ABI, whose costs increase with continued therapy for similar clinical outcomes.
